These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 37531032)

  • 81. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks.
    Lipton RB; Ailani J; Mullin K; Pavlovic JM; Tepper SJ; Dodick DW; Blumenfeld AM
    Headache; 2024; 64(7):859-864. PubMed ID: 38957980
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Is the right way to go in between? : Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant-post hoc results from an open label safety study (BHV3000-201).
    Gantenbein AR; Kleinschmidt A
    J Headache Pain; 2023 Mar; 24(1):33. PubMed ID: 36997843
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review.
    DeFalco AP; Lazim R; Cope NE
    Ann Pharmacother; 2021 May; 55(5):650-657. PubMed ID: 32909437
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Headache: Treatment update.
    Ogunlaja OI; Goadsby PJ
    eNeurologicalSci; 2022 Dec; 29():100420. PubMed ID: 36636337
    [TBL] [Abstract][Full Text] [Related]  

  • 86. To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and Rimegepant) and Calcitonin-Gene Related Peptide Receptor (CGRPR) Using Molecular Dynamics Simulations.
    Leung L; Liao S; Wu C
    ACS Chem Neurosci; 2021 Jul; 12(14):2629-2642. PubMed ID: 34184869
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment.
    Santos-Lasaosa S; Belvís R; Cuadrado ML; Díaz-Insa S; Gago-Veiga A; Guerrero-Peral AL; Huerta M; Irimia P; Láinez JM; Latorre G; Leira R; Pascual J; Porta-Etessam J; Sánchez Del Río M; Viguera J; Pozo-Rosich P
    Neurologia (Engl Ed); 2022 Jun; 37(5):390-402. PubMed ID: 35672126
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries.
    Sheykhzade M; Amandi N; Pla MV; Abdolalizadeh B; Sams A; Warfvinge K; Edvinsson L; Pickering DS
    Vascul Pharmacol; 2017 Mar; 90():36-43. PubMed ID: 28192258
    [TBL] [Abstract][Full Text] [Related]  

  • 89. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K; Michael RL; Rapoport AM
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [TBL] [Abstract][Full Text] [Related]  

  • 90. First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients.
    Yang Z; Wang X; Niu M; Wei Q; Zhong H; Li X; Yuan W; Xu W; Zhu S; Yu S; Liu J; Yan J; Kang W; Huang P
    J Headache Pain; 2024 Sep; 25(1):160. PubMed ID: 39333875
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
    Hutchinson S; Silberstein SD; Blumenfeld AM; Lipton RB; Lu K; Yu SY; Severt L
    Cephalalgia; 2021 Aug; 41(9):979-990. PubMed ID: 33874756
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
    Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
    Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
    [TBL] [Abstract][Full Text] [Related]  

  • 93. CGRP - a target for acute therapy in migraine: Clinical data.
    Messina R; Goadsby PJ
    Cephalalgia; 2019 Mar; 39(3):420-427. PubMed ID: 29616830
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
    Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB
    Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine.
    Wells-Gatnik WD; Pellesi L; Martelletti P
    Expert Rev Neurother; 2024 Nov; 24(11):1107-1117. PubMed ID: 39264231
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.
    Mullin K; Croop R; Mosher L; Fullerton T; Madonia J; Lipton RB
    Cephalalgia; 2024 Aug; 44(8):3331024241259456. PubMed ID: 39210835
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Gepants for abortive treatment of migraine: A network meta-analysis.
    Hong P; Tan T; Liu Y; Xiao J
    Brain Behav; 2020 Aug; 10(8):e01701. PubMed ID: 32525262
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Ubrogepant: Mechanism of action, clinical and translational science.
    Boinpally R; Shebley M; Trugman J
    Clin Transl Sci; 2024 Jan; 17(1):e13675. PubMed ID: 38266060
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review.
    Lo Castro F; Guerzoni S; Pellesi L
    Drug Healthc Patient Saf; 2021; 13():233-240. PubMed ID: 34849034
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Safety and Efficacy of Calcitonin Gene-related Peptide Receptor Antagonists and Selective Serotonin Receptor Agonist in the Management of Migraine: A Systematic Review and Meta-analysis.
    Singh P; Ponnada RK; Sharma R; Sumadhura B; Kumar A; Datusalia AK
    CNS Neurol Disord Drug Targets; 2024; 23(12):1474-1487. PubMed ID: 38847252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.